0000950170-24-036151.txt : 20240326 0000950170-24-036151.hdr.sgml : 20240326 20240326070814 ACCESSION NUMBER: 0000950170-24-036151 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240326 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240326 DATE AS OF CHANGE: 20240326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 24780882 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 vktx-20240326.htm 8-K 8-K
false000160767800016076782024-03-262024-03-26

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 26, 2024

 

Viking Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

 

 

 

Delaware

 

001-37355

 

46-1073877

(State or Other Jurisdiction of

Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (858) 704-4660

 

N/A

(Former Name, or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act

 

 

Title of Each Class

 

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.00001 per share

 

VKTX

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 7.01. Regulation FD.

On March 26, 2024, Viking Therapeutics, Inc. issued a press release announcing results from its oral Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01 (Regulation FD Disclosure) of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit Number

 

Description

99.1

 

Press Release, dated March 26, 2024.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

VIKING THERAPEUTICS, INC.

 

 

 

 

 

Date: March 26, 2024

By:

/s/ Brian Lian, Ph.D.

 

 

Brian Lian, Ph.D.

 

 

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 EX-99.1 2 vktx-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

img201808844_0.jpg 

 

 

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

 

Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days

 

VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events

 

Phase 2 Trial in Obesity Planned for 2H24

 

Conference Call Scheduled for 8:00 a.m. ET Today

 

SAN DIEGO, CA – March 26, 2024 – Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company’s Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity. Based on these Phase 1 results, the company plans to initiate a Phase 2 trial with the oral formulation of VK2735 in obesity later this year.

 

Highlights from the study results include:

 

Body Weight Reductions

 

The 28-day MAD study results highlight positive signs of clinical activity following treatment with oral VK2735. Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 5.3%. Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 3.3%. For doses ≥10 mg, placebo-adjusted reductions in mean body weight were maintained or improved at Day 34, six days after the last dose of VK2735 was administered, ranging up to 3.6% relative to placebo. An exploratory assessment of the proportion of subjects achieving at least 5% weight loss after 28 days demonstrated that up to 57% of VK2735-treated subjects achieved ≥5% weight loss, compared with 0% for placebo. Based on a preliminary evaluation of weight loss trajectory, the company believes that treatment duration beyond 28 days may provide further reductions in body weight.

 

“These Phase 1 results highlight VK2735’s promising early weight loss and tolerability profile when dosed as an oral tablet,” said Brian Lian, Ph.D., chief executive officer of Viking. “We believe these data indicate that longer treatment duration, at potentially higher doses, may result

 

 

in additional weight loss. We are particularly pleased with the initial safety and tolerability data, which suggest a differentiated profile with minimal gastrointestinal-related side effects. We believe that an oral agent with good tolerability could represent an attractive potential treatment option for patients with obesity. We look forward to exploring longer treatment windows and potentially higher doses in an upcoming Phase 2 trial.”

 

 

 

Observed Change in Body Weight Following 28 Days of Daily Dosing with Oral VK2735

 

Multiple Ascending Dose Level1,2

Placebo

(n=10)

VK2735

2.5 mg

(n=8)

VK2735

5 mg

(n=6)

VK2735

10 mg

(n=6)

VK2735

20 mg

(n=8)

VK2735

40 mg

(n=7)

Mean baseline body weight3

94.6 kg

102.3 kg

95.3 kg

97.1 kg

111.2 kg

90.0 kg

Mean change from baseline body weight4,5

-2.0 kg

-0.3 kg

-0.8 kg

-1.3 kg

-3.3 kg

-4.9 kg

Mean percent change from baseline4,5

-2.1%

-0.3%

-0.9%

-1.1%

-3.2%

-5.3%

Placebo-adjusted mean percent change from baseline4,5

-

1.8%

1.2%

1.0%

-1.1%

-3.3%

p-value vs. placebo5

-

-

-

-

0.23

0.0006

Percent reporting ≥5% weight loss

0%

0%

0%

0%

25%

57%

p-value vs. placebo6

-

-

-

-

0.18

0.015

Notes: 1) Population includes all randomized subjects who received at least one dose of study drug and had at least one planned post-baseline body weight assessment. 2) Patients treated with VK2735 were titrated to final doses as indicated: 2.5 mg cohort = 2.5 daily x 4 weeks; 5 mg cohort = 2.5 mg daily x 1 wk, 5 mg daily x 3 wks; 10 mg cohort = 5 mg daily x 1 wk, 10 mg daily x 3 wks; 20 mg cohort = 15 mg daily x 1 wk, 20 mg daily x 3 wks; 40 mg cohort = 20 mg daily x 1 wk, 40 mg daily x 3 wks. 3) All subjects enrolled were required to have baseline BMI ≥30 kg/m2. 4) Least squares mean. 5) Two-sided t test using mixed model for repeated measures. 6) Fisher’s exact test.

 

Safety and Tolerability

 

Oral VK2735 demonstrated encouraging safety and tolerability following 28 days of once-daily dosing. Among subjects receiving VK2735, all treatment emergent adverse events (TEAEs) reported to date have been mild or moderate, with the majority (76%) reported as mild. Similarly, all observed gastrointestinal (GI) adverse events have been reported as mild or moderate, with the majority (79%) reported as mild. Mild nausea was reported in five (14%) VK2735-treated subjects. Vomiting was not reported among any VK2735-treated subjects. Diarrhea was reported in one subject (3%) receiving VK2735 compared with two subjects (20%) receiving placebo. Overall, no clinically meaningful differences were reported for GI-related adverse events among subjects treated with VK2735 compared with placebo. In addition, no serious adverse events (SAEs) have been reported to date.

 

Common GI-Related Adverse Events Following 28 Days of Daily Dosing with Oral VK2735

 

Common AEs,

No. of Subjects reporting, (%)

Placebo

(n=10)

VK2735 2.5 mg

(n=8)

VK2735

5 mg

(n=7)

VK2735

10 mg

(n=6)

VK2735

20 mg

(n=8)

VK2735

40 mg

(n=8)

VK2735

Combined

(n=37)

Nausea

 

 

 

 

 

 

 

 

 

    Mild

    Moderate

    Severe

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1 (14%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

2 (25%)

0 (0%)

0 (0%)

2 (25%)

0 (0%)

0 (0%)

5 (14%)

0 (0%)

0 (0%)

Vomiting

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Diarrhea

2 (20%)

0 (0%)

0 (0%)

0 (0%)

1 (13%)

0 (0%)

1 (3%)

Constipation

2 (20%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo.

 

Based on the encouraging weight loss, as well as the safety and tolerability results to date, the company has elected to continue further dose escalation in this study. Viking also plans to initiate a Phase 2 trial of oral VK2735 in patients with obesity in the second half of 2024.

 

The Phase 1 MAD study of oral VK2735 is an extension of the company’s Phase 1 single ascending dose (SAD)/MAD trial of VK2735 administered subcutaneously. The oral portion of the trial is a randomized, double-blind, placebo-controlled study in healthy adults with a minimum body mass index of 30 kilograms per meter squared. The primary objective of the study was to evaluate the safety and tolerability of VK2735 administered as an oral tablet once daily for 28 days. Exploratory pharmacodynamic measures included assessments of changes in body weight and other metrics.

 

Conference Call

 

Management will host a conference call to discuss results from the company’s Phase 1 trial of an oral formulation of VK2735 today at 8:00 am Eastern. To participate in the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until April 2, 2024, by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering conference ID #6296711. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking’s website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of Viking’s website for 30 days.

 

About GLP-1 and Dual GLP-1/GIP Agonists

 

Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound®.

 

 

 

About Viking Therapeutics, Inc.

 

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for obesity demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 1 trial. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

 

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs activities, timelines and milestones, including the Company’s plans for VK2735 and its prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and the company's other incretin receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission, including Viking's Annual Report on Form 10-K for the year ended December 31, 2023 including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements except as required by law.

 

 

 

Contacts:

 

Viking Therapeutics, Inc.

Greg Zante

Chief Financial Officer

858-704-4672

gzante@vikingtherapeutics.com

 

Vida Strategic Partners

Stephanie Diaz (Investors)

415-675-7401

sdiaz@vidasp.com

 

Tim Brons (Media)

415-675-7402

tbrons@vidasp.com

 

 GRAPHIC 3 img201808844_0.jpg GRAPHIC begin 644 img201808844_0.jpg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end EX-101.SCH 4 vktx-20240326.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address State Or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address City Or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Address Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation State Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre Commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address Address Line2 Entity Address, Address Line Two Entity Address Address Line1 Entity Address, Address Line One Security12b Title Title of 12(b) Security Document Type Document Type XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document and Entity Information
Mar. 26, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 26, 2024
Entity Registrant Name Viking Therapeutics, Inc.
Entity Central Index Key 0001607678
Entity Emerging Growth Company false
Entity File Number 001-37355
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-1073877
Entity Address, Address Line One 9920 Pacific Heights Blvd
Entity Address, Address Line Two Suite 350
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 704-4660
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol VKTX
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports vktx-20240326.htm vktx-20240326.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vktx-20240326.htm": { "nsprefix": "vktx", "nsuri": "http://vikingtherapeutics.com/20240326", "dts": { "inline": { "local": [ "vktx-20240326.htm" ] }, "schema": { "local": [ "vktx-20240326.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_d285cd9f-ae6b-4c71-9948-a758c22c7840", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "vktx-20240326.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d285cd9f-ae6b-4c71-9948-a758c22c7840", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "vktx-20240326.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security12b Title", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vikingtherapeutics.com/20240326/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-036151-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-036151-xbrl.zip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end XML 16 vktx-20240326_htm.xml IDEA: XBRL DOCUMENT 0001607678 2024-03-26 2024-03-26 false 0001607678 8-K 2024-03-26 Viking Therapeutics, Inc. DE 001-37355 46-1073877 9920 Pacific Heights Blvd Suite 350 San Diego CA 92121 858 704-4660 false false false false Common Stock, par value $0.00001 per share VKTX NASDAQ false